Latest News for: Novartis

Edit

Novartis receives third FDA approval for oral Fabhalta® (iptacopan) – the first and only treatment ...

Nasdaq Globe Newswire 20 Mar 2025
Novartis receives third FDA approval for oral Fabhalta® (iptacopan) – the first and only treatment approved in C3 glomerulopathy (C3G) ... .
Edit

Novartis receives third FDA approval for oral Fabhalta® (iptacopan) - the first and only treatment approved in C3 glomerulopathy (C3G)

PR Newswire 20 Mar 2025
EAST HANOVER, N.J., March 20, 2025 /PRNewswire/ -- Novartis today announced that oral Fabhalta® (iptacopan) has received U.S ... Novartis Pharmaceuticals Corp; March 2025 ... Novartis Media Relations ... Novartis Investor Relations.
Edit

NFL names Novartis first-ever corporate pharmaceutical partner

Indianapolis Recorder 19 Mar 2025
The National Football League (NFL) announced Novartis as its first-ever corporate pharmaceutical partner on March 13 ... Novartis, a global leader in innovative medicines, will collaborate with the NFL on key health initiatives.
Edit

New Novartis Phase III data demonstrate meaningful efficacy and safety results of intrathecal onasemnogene abeparvovec in broad patient population with SMA

PR Newswire 19 Mar 2025
... Medical Officer, Novartis ... About Novartis Novartis is an innovative medicines company ... Novartis Media RelationsE-mail ... Novartis Investor RelationsCentral investor relations line ... SOURCE Novartis.
Edit

Novartis to lay off 427 in North Jersey as drug patent expires

northjersey.com 18 Mar 2025
In 2022, Novartis said it would cut 8,000 jobs globally, Reuters reported, which would save the company $1 billion over the next two years ... Novartis has over ... Novartis shrinking its Morris County campus.
Edit

Circulating DNA RNA Patent Landscape Report And Forecast 2024-2032: Nantomics, Genentech, And Novartis Are Pivotal ...

MENA FN 14 Mar 2025
(MENAFN - GlobeNewsWire - Nasdaq) Dublin, March 14, 2025 (GLOBE NEWSWIRE) -- The "Circulating DNA RNA Patent Landscape Report and Forecast 2024-2032" report has been added to ... .
Edit

'Too Many Tests': Expert Panel Questions Novartis Trial Protocol For Rare Kidney & Blood Disorder Drug

News18 11 Mar 2025
Novartis spokesperson told News18 that the company is in the process of reviewing the minutes of the meeting and post consultation with our global teams, it will take the necessary next steps ... .
Edit

mRNA Cancer Therapeutics Patent Landscape Report and Forecast 2024-2032 Featuring Pfizer, Moderna, and Novartis with ...

Nasdaq Globe Newswire 11 Mar 2025
The report also highlights major companies shaping the field, such as Pfizer, Moderna, and Novartis, detailing their contributions and patent portfolios. .
×